1. Platt, OS, Thorington, BD, Brambilla, DJ, et al. Pain in sickle cell disease. Rates and risk factors. New Engl J Med 1991; 325: 11–16.
Google Scholar | Crossref | Medline | ISI2. Telfer, P, Kaya, B. Optimizing the care model for an uncomplicated acute pain episode in sickle cell disease. Hematology Am Soc Hematol Educ Program 2017; 2017: 525–533.
Google Scholar | Crossref | Medline3. Yawn, BP, Buchanan, GR, Afenyi-Annan, AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312: 1033–1048.
Google Scholar | Crossref | Medline | ISI4. Gillis, VL, Senthinathan, A, Dzingina, M, et al. Management of an acute painful sickle cell episode in hospital: summary of NICE guidance. BMJ 2012; 344: e4063.
Google Scholar | Crossref | Medline5. Brandow, AM, Carroll, CP, Creary, S, et al. American society of hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv 2020; 4: 2656–2701.
Google Scholar | Crossref | Medline6. Akinsola, B, Hagbom, R, Zmitrovich, A, et al. Impact of intranasal fentanyl in nurse initiated protocols for sickle cell vaso-occlusive pain episodes in a pediatric emergency department. Am J Hematol. Epub ahead of print 17 May 2018. DOI: 10.1002/ajh.25144.
Google Scholar | Crossref | Medline7. Savage, WJ, Buchanan, GR, Yawn, BP, et al. Evidence gaps in the management of sickle cell disease: a summary of needed research. Am J Hematol 2015; 90(4): 273–275.
Google Scholar | Crossref | Medline8. Ballas, SK, Gupta, K, Adams-Graves, P. Sickle cell pain: a critical reappraisal. Blood 2012; 120: 3647–3656.
Google Scholar | Crossref | Medline | ISI9. Kopecky, EA, Jacobson, S, Joshi, P, et al. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clin Pharmacol Ther 2004; 75(3): 140–146.
Google Scholar | Crossref | Medline10. Somogyi, AA, Barratt, DT, Coller, JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81: 429–444.
Google Scholar | Crossref | Medline11. Han, J, Zhou, J, Saraf, SL, et al. Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug Saf 2018; 27: 479–486.
Google Scholar | Crossref | Medline12. Allain, F, Minogianis, EA, Roberts, DC, et al. How fast and how often: the pharmacokinetics of drug use are decisive in addiction. Neurosci Biobehav Rev 2015; 56: 166–179.
Google Scholar | Crossref | Medline13. Jacobson, SJ, Kopecky, EA, Joshi, P, et al. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet 1997; 350: 1358–1361.
Google Scholar | Crossref | Medline | ISI14. Telfer, P, Barroso, F, Newell, K, et al. Evaluation of a non-parenteral opioid analgesia protocol for acute sickle cell pain episodes in children. J Clin Med 2019; 8: 1728.
Google Scholar | Crossref | Medline15. Telfer, P, Bahal, N, Lo, A, et al. Management of the acute painful crisis in sickle cell disease – a re-evaluation of the use of opioids in adult patients. Br J Haematol 2014; 166(2): 157–164.
Google Scholar | Crossref | Medline16. Lennernas, B, Hedner, T, Holmberg, M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005; 59(2): 249–253.
Google Scholar | Crossref | Medline17. Kelly, GS, Stewart, RW, Strouse, JJ, et al. Intranasal fentanyl improves time to analgesic delivery in sickle cell pain crises. Am J Emerg Med 2018; 36(7): 1305–1307.
Google Scholar | Crossref | Medline18. Fein, DM, Avner, JR, Scharbach, K, et al. Intranasal fentanyl for initial treatment of vaso-occlusive crisis in sickle cell disease. Pediatr Blood Cancer 2017; 64(6): 26332.
Google Scholar | Crossref19. Telfer, P, Criddle, J, Sandell, J, et al. Intranasal diamorphine for acute sickle cell pain. Arch Dis Child 2009; 94(12): 979–980.
Google Scholar | Crossref | Medline20. Elander, J, Bij, D, Kapadi, R, et al. Development and validation of the satisfaction with treatment for pain questionnaire (STPQ) among patients with sickle cell disease. Br J Haematol 2019; 187(1): 105–116.
Google Scholar | Crossref | Medline21. Elander, J, Lusher, J, Bevan, D, et al. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manage 2004; 27(2): 156–169.
Google Scholar | Crossref | Medline22. Gezmu, M, Flournoy, N. Group up-and-down designs for dose-finding. J Stat Plan Infer 2006; 136: 1749–1764.
Google Scholar | Crossref | ISI23. Buchanan, ID, Woodward, M, Reed, GW. Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome. Pediatr Blood Cancer 2005; 45: 716–724.
Google Scholar | Crossref | Medline24. Orringer, EP, Casella, JF, Ataga, KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA 2001; 286: 2099–2106.
Google Scholar | Crossref | Medline | ISI25. Bartolucci, P, Habibi, A, Khellaf, M, et al. Score predicting acute chest syndrome during vaso-occlusive crises in adult sickle-cell disease patients. Ebiomedicine 2016; 10: 305–311.
Google Scholar | Crossref | Medline26. Telen, MJ, Wun, T, McCavit, TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood 2015; 125: 2656–2664.
Google Scholar | Crossref | Medline27. Tanabe, P, Silva, S, Bosworth, HB, et al. A randomized controlled trial comparing two vaso-occlusive episode (VOE) protocols in sickle cell disease (SCD). Am J Hematol 2018; 93(2): 159–168.
Google Scholar | Crossref | Medline28. Hardwick, WE, Givens, TG, Monroe, KW, et al. Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. Pediatric Emergency Care 1999; 15: 179–182.
Google Scholar | Crossref | Medline | ISI29. Wright, SW, Norris, RL, Mitchell, TR. Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. Ann Emerg Med 1992; 21(8): 925–928.
Google Scholar | Crossref | Medline30. Dampier, CD, Smith, WR, Wager, CG, et al. IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials 2013; 10(2): 319–331.
Google Scholar | SAGE Journals | ISI31. Glassberg, J, Simon, J, Patel, N, et al. Derivation and preliminary validation of a risk score to predict 30-day ED revisits for sickle cell pain. Am J Emerg Med 2015; 33(10): 1396–1401.
Google Scholar | Crossref | Medline32. Smith, WR, McClish, DK, Dahman, BA, et al. Daily home opioid use in adults with sickle cell disease: the PiSCES project. J Opioid Manag 2015; 11(3): 243–253.
Google Scholar | Crossref | Medline